An Indian-made next-generation heart stent has achieved a landmark global recognition, outperforming a leading US-made device in a major clinical trial presented at one of the world’s most prestigious cardiology events — TCT 2025 (Transcatheter Cardiovascular Therapeutics), held in San Francisco.
At the conference, eminent Indian cardiologist Dr. Upendra Kaul, Chairman and Dean of Delhi’s Batra Hospital, unveiled the results of the TUXEDO-2 trial, which compared India’s Supraflex Cruz stent with the globally recognized Xience from the USA.
Conducted across 66 leading cardiology centres in India, the study focused on a highly complex patient population — individuals with diabetes and advanced multi-vessel coronary artery disease, of whom nearly 80% had triple-vessel disease.
The findings were striking: Supraflex Cruz proved non-inferior to Xience, with a lower Target Lesion Failure (TLF) — a key composite measure that includes cardiac death, target vessel myocardial infarction, and the need for repeat procedures. The Indian stent also showed a numerically lower one-year heart attack rate.
Manufactured in Surat, Supraflex Cruz was hailed at TCT 2025 as a milestone in India’s medical device innovation and global competitiveness. The trial was led by Dr. Upendra Kaul, with Dr. Sripal Bangalore as Co-Chairman and Dr. Priyadarshini Arambam as Project Director.
Also Read
